Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments 2-5 Novartis continues to ...

When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely ...

Raising breast cancer awareness through unity: Over 2,000 participants advocate for early detection and support The largest human pink ribbon formation sets a record, with the attendance of Deputy ...

Job Title Sort ascending Business Location Site Date Posted Equipment Specialist (m/w/d), Kundl, Tirol, Österreich Regulär, Full time Innovative Medicines Austria Kundl Oct 18, 2024 Trainee Marketing ...

Job Title Sort ascending Business Location Site Date Posted Senior Scientist - in-vivo pharmacology/oncology (Radioligand Therapy) (80-100%*) Regular, Full time Pharma Research Switzerland Basel (City ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...